0001104659-23-070827.txt : 20230613 0001104659-23-070827.hdr.sgml : 20230613 20230613163019 ACCESSION NUMBER: 0001104659-23-070827 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230608 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230613 DATE AS OF CHANGE: 20230613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 231011574 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: (215) 921-7600 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 8-K 1 tm2318498d2_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 8, 2023

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

001-33497

71-0869350

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

3675 Market Street, Philadelphia, PA 19104

(Address of Principal Executive Offices, and Zip Code)

215-921-7600

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock Par Value $0.01		FOLD		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 8, 2023, Amicus Therapeutics, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, as described below under Item 5.07, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to eliminate or limit the personal liability of certain Company officers for monetary damages for breach of fiduciary duty as an officer, except to the extent such an exemption from liability or limitation thereof is not permitted by Delaware General Corporation Law (the “Amendment”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on June 8, 2023 (the “Certificate of Amendment”). The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 hereto and is incorporated by reference herein.

Item 5.07 - Submission of Matters to a Vote of Security Holders.

At the 2023 Annual Meeting of Stockholders of the Company, held on June 8, 2023, the Company’s stockholders elected Lynn D. Bleil and Bradley L. Campbell as Class I directors to serve a three-year term expiring at the 2026 Annual Meeting of Stockholders and until their respective successors have been elected. In addition, the stockholders (i) approved the Amended and Restated 2007 Equity Incentive Plan, (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, (iii) approved, on an advisory basis, the compensation paid to the Company’s named executive officers, (iv) approved, on an advisory basis, every year as the frequency of the stockholder advisory vote on compensation paid to the Company’s named executive officers, (v) approved the adoption of the Amicus Therapeutics, Inc. 2023 Employee Stock Purchase Plan, and (vi) approved the amendment to the Company’s Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company. The final voting results on these matters were as follows:

1.

Election of Directors.

Nominee		Votes For			Votes Withheld			Broker Non-Votes
Lynn D. Bleil		230,953,927			7,130,503			9,633,404
Bradley L. Campbell		234,192,987			3,891,443			9,633,404

2.

Approval of the Amended and Restated 2007 Equity Incentive Plan.

Votes For			Votes Against			Votes Abstain			Broker Non-Votes
233,613,440			4,249,485			221,505			9,633,404

3.

Ratification of Ernst & Young LLC as the Company's Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023.

Votes For			Votes Against			Votes Abstain			Broker Non-Votes
244,703,546			2,910,798			103,490			-

4.

Approval, on an advisory basis, of the Company's executive compensation.

Votes For			Votes Against			Votes Abstain			Broker Non-Votes
234,564,815			2,990,153			529,462			9,633,404

5.

Approval, on an advisory basis, of the frequency with which the Company will hold an advisory vote on executive compensation.

One Year			Two Years			Three Years		Votes Abstain			Broker Non-Votes
237,871,957			41,044			118,319		53,110			-

Based on the votes above, the Company will hold an advisory vote on the compensation of its named executive officers every year until the next required vote on the frequency of executive compensation is held.

6.

Approval of the Amicus Therapeutics, Inc. 2023 Employee Stock Purchase Plan.

Votes For			Votes Against			Votes Abstain			Broker Non-Votes
236,770,951			868,243			445,236			9,633,404

7.

Approval of the Amendment to the Company’s Restated Certificate of Incorporation to limit the liability of certain officers.

Votes For			Votes Against			Votes Abstain			Broker Non-Votes
182,903,050			55,130,799			50,581			9,633,404

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

Exhibit No.	Description
3.1	Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation, dated June 8, 2023

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signature Page

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMICUS THERAPEUTICS, INC.
Date: June 13, 2023	By:	/s/ Ellen S. Rosenberg
	Name: Ellen S. Rosenberg
	Title: Chief Legal Officer and Corporate Secretary

EX-3.1 2 tm2318498d2_ex3-1.htm EXHIBIT 3.1

Exhibit 3.1

CERTIFICATE OF AMENDMENT OF THE
RESTATED CERTIFICATE OF
INCORPORATION

OF

AMICUS THERAPEUTICS, INC.

AS OF JUNE 8, 2023

(Pursuant to § 242 of the General Corporation Law of the State of Delaware)

_________________

AMICUS THERAPEUTICS, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify:

1.            A Restated Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”) was filed with the Secretary of State of the State of Delaware on June 5, 2007.

2.            A Certificate of Amendment of the Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on January 17, 2012.

3.            A Certificate of Amendment of the Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June 10, 2015.

4.            A Certificate of Amendment of the Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on June 8, 2018.

FIRST:                  Pursuant to Section 242 of the General Corporation Law of the State of Delaware (“DGCL”), the Board of Directors of the Corporation duly adopted resolutions on April 13, 2023 setting forth an amendment to the Certificate of Incorporation of the Corporation, as amended; declaring said amendment to be advisable; and directing that the amendment be presented to the stockholders of the Corporation at the next annual meeting thereof. The resolution adopted by the Board provided that the Certificate of Incorporation filed on June 5, 2007, as amended January 17, 2012, June 10, 2015 and June 8, 2018, be further amended by deleting ARTICLE SIXTH and inserting the following in lieu thereof such that ARTICLE SIXTH shall read in its entirety as follows:

“SIXTH: No director of the Corporation shall be personally liable to the Corporation or to any of its stockholders for monetary damages for breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability; provided, however, that to the extent required from time to time by applicable law, this Article Sixth shall not eliminate or limit the liability of a director, to the extent such liability is provided by applicable law, (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transactions from which the director derived an improper personal benefit. No amendment to or repeal of this Article Sixth shall apply to or have any effect on the liability or alleged liability of any director for or with respect to any acts or omissions of such director occurring prior to the effective date of such amendment or repeal. This Article shall not eliminate or limit the liability of a director for any act or omission occurring prior to June 5, 2007.

No officer of the Corporation shall be personally liable to the Corporation or to any of its stockholders for monetary damages for breach of fiduciary duty as an officer, notwithstanding any provision of law imposing such liability; provided, however, that to the extent required from time to time by applicable law, this Article Sixth shall not eliminate or limit the liability of an officer, to the extent such liability is provided by applicable law, (i) for any breach of the officer’s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for any transactions from which the officer derived an improper personal benefit or (iv) in any action by or in the right of the Corporation. This Article shall not eliminate or limit the liability of an officer for any act or omission occurring prior to June 8, 2023.”

SECOND:             Pursuant to the resolution of the Board of Directors of the Corporation, the stockholders of the Corporation duly approved and adopted said amendment at a duly called annual meeting of the Corporation’s stockholders, at which meeting the necessary number of shares were voted in favor of the amendment in accordance with Sections 222 and 242 of the DGCL.

THIRD:                 This amendment shall become effective upon filing.

[Remainder of page intentionally left blank]

THE UNDERSIGNED, being the Chief Legal Officer and Corporate Secretary of the Corporation, for the purpose of amending the Corporation’s Certificate of Incorporation pursuant to the DGCL, does make this certificate, hereby declaring and certifying that this is my act and deed on behalf of the Corporation this 8^th day of June, 2023.

	AMICUS THERAPEUTICS, Inc.


	By:	/s/ Ellen S. Rosenberg
	Name:	Ellen S. Rosenberg
	Title:	Chief Legal Officer and Corporate Secretary

EX-101.SCH 3 fold-20230608.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fold-20230608_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fold-20230608_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jun. 08, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jun. 08, 2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-33497
Entity Registrant Name	AMICUS THERAPEUTICS, INC.
Entity Central Index Key	0001178879
Entity Tax Identification Number	71-0869350
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3675 Market Street
Entity Address, City or Town	Philadelphia
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19104
City Area Code	215
Local Phone Number	921-7600
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock Par Value $0.01
Trading Symbol	FOLD
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 tm2318498d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001178879 2023-06-08 2023-06-08 iso4217:USD shares iso4217:USD shares 0001178879 false --12-31 8-K 2023-06-08 AMICUS THERAPEUTICS, INC. DE 001-33497 71-0869350 3675 Market Street Philadelphia PA 19104 215 921-7600 false false false false Common Stock Par Value $0.01 FOLD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://amicustherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2318498d2_8k.htm fold-20230608.xsd fold-20230608_lab.xml fold-20230608_pre.xml tm2318498d2_ex3-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2318498d2_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2318498d2_8k.htm" ] }, "labelLink": { "local": [ "fold-20230608_lab.xml" ] }, "presentationLink": { "local": [ "fold-20230608_pre.xml" ] }, "schema": { "local": [ "fold-20230608.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fold", "nsuri": "http://amicustherapeutics.com/20230608", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318498d2_8k.htm", "contextRef": "From2023-06-08to2023-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://amicustherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2318498d2_8k.htm", "contextRef": "From2023-06-08to2023-06-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://amicustherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-070827-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-070827-xbrl.zip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end